However, based on previous research, prostate cancer can develop resistance to small molecule drugs through various mechanisms, such as the secretion of IGF-1 by adipocytes and the regulation of m6a methylation levels [49, 50]. This evidence concerns the gene IGF1 and prostate carcinoma.